1naresh

Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1nareshArray
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)

Table 5: Meta-regression analysis of follow-up time affecting heterogeneity (ASA plus clopidogrel versus ASA plus ticagrelor)
Variable Coefficient (95% CI) Standard Error T P Value
Thromboembolic complications 0.005 (−0.007–0.017) 0.005 1.106 .338
Hemorrhagic complications 0.002 (−0.010–0.014) 0.005 0.42 .69
Perioperative mortality related to antiplatelet medication 0.012 (−0.042–0.066) 0.021 0.59 .581
Good clinical outcomes −0.006 (−0.020–0.008) 0.005 –1.22 .289

Variable	Coefficient (95% CI)	Standard Error	T	P Value
Thromboembolic complications	0.005 (−0.007–0.017)	0.005	1.106	.338
Hemorrhagic complications	0.002 (−0.010–0.014)	0.005	0.42	.69
Perioperative mortality related to antiplatelet medication	0.012 (−0.042–0.066)	0.021	0.59	.581
Good clinical outcomes	−0.006 (−0.020–0.008)	0.005	–1.22	.289